Technical Analysis for CTXR - Citius Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 2.52 -7.69% -0.21
CTXR closed down 7.69 percent on Wednesday, April 25, 2018, on 87 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong N/A Down Down
See historical CTXR trend table...

Date Alert Name Type % Chg
Apr 25 New 52 Week Closing Low Bearish 0.00%
Apr 25 Lower Bollinger Band Walk Weakness 0.00%
Apr 25 Stochastic Reached Oversold Weakness 0.00%
Apr 25 Below Lower BB Weakness 0.00%
Apr 25 Lower Bollinger Band Touch Weakness 0.00%
Apr 25 Oversold Stochastic Weakness 0.00%
Apr 24 Lower Bollinger Band Walk Weakness -7.69%
Apr 24 Lower Bollinger Band Touch Weakness -7.69%
Apr 23 Outside Day Range Expansion -7.35%
Apr 23 Lower Bollinger Band Touch Weakness -7.35%

Older signals for CTXR ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.
Is CTXR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.49
52 Week Low 2.5
Average Volume 29,565
200-Day Moving Average 0.0
50-Day Moving Average 3.1708
20-Day Moving Average 2.9375
10-Day Moving Average 2.816
Average True Range 0.2005
ADX 37.86
+DI 8.54
-DI 25.62
Chandelier Exit (Long, 3 ATRs ) 2.6485
Chandelier Exit (Short, 3 ATRs ) 3.1015
Upper Bollinger Band 3.269
Lower Bollinger Band 2.606
Percent B (%b) -0.13
BandWidth 22.570213
MACD Line -0.1442
MACD Signal Line -0.1228
MACD Histogram -0.0214
Fundamentals Value
Market Cap 20.79 Million
Num Shares 8.25 Million
EPS -1.98
Price-to-Earnings (P/E) Ratio -1.27
Price-to-Sales 0.00
Price-to-Book 1.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.88
Resistance 3 (R3) 2.91 2.83 2.82
Resistance 2 (R2) 2.83 2.73 2.81 2.80
Resistance 1 (R1) 2.67 2.68 2.63 2.64 2.78
Pivot Point 2.59 2.59 2.57 2.57 2.59
Support 1 (S1) 2.43 2.49 2.39 2.40 2.26
Support 2 (S2) 2.35 2.44 2.33 2.24
Support 3 (S3) 2.19 2.35 2.22
Support 4 (S4) 2.16